Dr Amol Akhade

Dr Amol Akhade

Senior Consultant – Medical & Precision Oncology

Specialities

Oncology

About Doctor

Dr. Amol Akhade is a renowned medical and haemato-oncologist with over 18 years of experience in treating cancer, focusing on personalised
approaches and innovative therapies. Trained at the Tata Memorial Hospital in Mumbai, a premier cancer institute in India, he currently practices at Fortis Hospital, Mulund, providing compassionate and advanced care to cancer patients. He is highly skilled and experienced in treating solid tumours and haematologic malignancies, including lymphoma, leukaemia, and myeloma. He is also an expert in performing both autologous and allogeneic bone marrow transplants.

Apart from his clinical responsibilities, Dr Akhade has a deep interest in medical education and research, particularly in the field of oncology. His research findings have been published in reputed journals. He is actively engaged in multidisciplinary tumour boards, where he collaborates with other cancer specialists to determine the best treatment plan for patients. A DNB faculty and a recognised speaker, Dr Akhade’s special interests also include clinical trials and real-world data in oncology.

Qualification

  • MBBS: KEM Hospital, Mumbai
  • MD (Internal Medicine): KEM Hospital, Mumbai
  • DM (Medical Oncology): Tata Memorial Hospital, Mumbai

Area of Expertise

  • Precision Oncology
  • Chemotherapy, Immunotherapy, and Targeted Therapy for Solid Tumours
  • Bone Marrow Transplant
  • Haematologic Malignancies
  • Head and Neck Cancers
  • Lung Cancer
  • Breast Cancer
  • GI and Gynaecological Cancers

Work Experience

  • A retrospective audit of clinicopathological attributes and treatment outcomes of adolescent and young adult non-Hodgkin lymphomas from a tertiary care center (Indian Journal of Medical and Paediatric Oncology)
  • Global Consequences of the US FDA’s accelerated approval of cancer drugs (Lancet Oncology)
  • Pembrolizumab weight-based dosing – A call for policy change (Indian Journal of Medical and Paediatric Oncology)
  • Pembrolizumab weight-based dosing: Conviction and lacuna in adopting a cost-saving approach – a survey report (Indian Journal of Medical and Paediatric Oncology)
  • To give or not to give adjuvant chemotherapy in breast cancer? Can CanAssist breast assist? (South Asian Journal of Cancer)
  • Cancer research in lower- and middle-income countries (LMICs): How can we improve? (Indian Journal of Cancer)
  • CDK4/6 inhibitors for adjuvant therapy in early breast cancer – Do we have a clear winner? (ecancermedicalscience)
  • Could We Have Improved on ADAURA? Refining Global Research Practices to Reduce Cancer Care Disparities (JCO Global Oncology)
  • Consensus Guidelines for the Use of Cyclin-Dependent Kinase (CDK) 4/6 Inhibitors in the Management of Hormone Receptor Positive (HR+ve), Her2-ve Early Breast Cancer (EBC) (South Asian Journal of Cancer)
  • Geriatric oncology in LMICs: It is time to mature (BMJ Oncology)